IP Library Granted Patent US 10,238,754
Granted Patent B2
US 10,238,754 · App. 15/482,117 · Granted Mar 26, 2019

Lipid nanoparticle compositions and methods for MRNA delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,238,754
App. No.
15/482,117
Granted
Mar 26, 2019
Kind
B2
Abstract

Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.

Claims (13)

1. A method for delivery of messenger RNA (mRNA) for in vivo production of a protein, comprising administering to a human, a composition comprising an mRNA that encodes a protein or a peptide, wherein the mRNA is encapsulated within a lipid nanoparticle and wherein the administering of the composition results in expression of the protein or peptide encoded by the mRNA that is detectable in serum at least 72 hours after administration, wherein the lipid nanoparticle comprises one or more PEG-modified lipids.

2. The method of claim 1 , wherein the lipid nanoparticle has a size of less than about 100 nm.

3. The method of claim 1 , wherein the mRNA comprises at least one modification that enhances the stability of the mRNA relative to its unmodified counterpart.

4. The method of claim 3 , wherein the modification comprises a modified nucleotide.

5. The method of claim 4 , wherein modified nucleotide is pseudouridine.

6. The method of claim 3 , wherein the mRNA comprises a 5′ untranslated region.

7. The method of claim 3 , wherein the mRNA comprises a 3′ untranslated region.

8. The method of claim 3 , wherein the mRNA comprises a cap structure.

9. The method of claim 3 , wherein the mRNA comprises a poly A tail.

10. The method of claim 1 , wherein the mRNA is unmodified.

11. The method of claim 1 , wherein the composition is administered by intravenous injection.

12. The method of claim 1 , wherein the composition is administered by pulmonary delivery.

13. The method of claim 1 , wherein the composition is administered by intramuscular delivery.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2017
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: RANA THERAPEUTICS, INC.
Reel/Frame 044353/0922 →
CHANGE OF NAME Recorded Nov 2, 2017
From: RANA THERAPEUTICS, INC.
To: TRANSLATE BIO, INC.
Reel/Frame 044354/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2017
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 043755/0918 →
Cited By (11)
US 12,186,387 US 12,208,136 US 12,239,735 US 12,280,117 US 12,351,834 US 12,398,379 US 12,458,604 US 12,559,450 US 12,576,040 US 12,605,464 US 12,703,858